Skip to main content
ViaCell will begin to enroll patients in a Phase I/II clinical trial of CB001, a highly purified population of stem cells that has been isolated from umbilical cord blood and multiplied using the company’s patented Selective Amplification technology.

In The Pipeline

February 1, 2004

ViaCell will begin to enroll patients in a Phase I/II clinical trial of CB001, a highly purified population of stem cells that has been isolated from umbilical cord blood and multiplied using the companys patented Selective Amplification technology.